WallStSmart
MDT

Medtronic PLC

NYSE: MDT · HEALTHCARE · MEDICAL DEVICES

$80.97
+2.02% today

Updated 2026-04-29

Market cap
$106.97B
P/E ratio
23.27
P/S ratio
3.02x
EPS (TTM)
$3.58
Dividend yield
3.38%
52W range
$77 – $105
Volume
8.3M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Medtronic PLC (MDT) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$80.97
Consensus
$108.89
+34.48%
2030 Target
$441.81
+445.65%
DCF
$108.03
+26.53% MoS
20 analysts:
12 Buy8 Hold0 Sell

Management guidance

No specific CEO revenue targets for 2026-2030 period identified in available data. Management is focused on MiniMed spinoff (completed March 2026) and strategic portfolio optimization. FY2026 guidance implies continued mid-single-digit organic growth trajectory.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$727.69
$46.9B Rev × 20x P/S
Base case (2030)
$441.81
$46.9B Rev × 12x P/S
Bear case (2030)
$294.54
$46.9B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$31.2B$32.4B$33.5B$36.5B$39.0B$41.5B$44.1B$46.9B
Revenue growth—3.6%3.6%8.9%6.7%6.6%6.2%6.3%
EPS$5.30$5.21$5.50$5.70$6.14$6.58$7.05$7.54
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$337.86$363.85$389.84$415.82$441.81

Catalysts & risks

Growth catalysts
+ MiniMed spinoff completion (March 2026) - separation simplifies growth narrative for core MDT
+ FDA clearance for Stealth AXiS surgical system for cranial/ENT procedures - expands neurosurgery portfolio
+ $550M Scientia Vascular acquisition - strengthens neurovascular access portfolio
+ FDA approval for OmniaSecure defibrillation lead for conduction system pacing - new indication expansion
+ Continued robotics/minimally invasive surgery adoption across cardiac, neuro, and surgical segments
Key risks
- MiniMed spinoff execution risk and potential EPS dilution from separation costs
- Medical device industry competitive intensity from Stryker, Boston Scientific, Abbott in core markets
- Regulatory delays or clinical trial setbacks in key programs (cardiac, neurosurgery, diabetes spinoff)
- Pricing pressure in developed markets and emerging market reimbursement headwinds
- Integration complexity of recent acquisitions (Scientia Vascular) and spinoff operational separation

Methodology

Medtronic PLC's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 20 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.